To determine whether any specific subset of BMDCs was recruited by resident stroma interacting with the tumors, we next immunostained tumor tissues using a panel of antibodies that recognize cellular subsets in the TME, including αSMA as a marker of CAFs (20, 21), CD34 as a marker of TECs (12, 22, 23), CD11b as a marker of TAMs (24–26), and coexpression of CD11b and GR1 as a marker of MDSCs (27). The gene discussed is CD34; the disease is neoplasm.